NCIt definition : An orally available inhibitor of receptor tyrosine kinases anaplastic lymphoma kinase
(ALK) and the epidermal growth factor receptor (EGFR) with potential antineoplastic
activity. Brigatinib binds to and inhibits ALK kinase and ALK fusion proteins as well
as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase,
disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible
tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK
belongs to the insulin receptor superfamily and plays an important role in nervous
system development; ALK dysregulation and gene rearrangements are associated with
a series of tumors. EGFR is overexpressed in a variety of cancer cell types.;
UNII : HYW8DB273J;
InChIKey : AILRADAXUVEEIR-UHFFFAOYSA-N;
CAS number : 1197953-54-0; a href https://gsrs.ncats.nih.gov/ginas/app/beta/browse-substance?search 1197953-54-0
alt lien vers site G-SRS target _blank img src /img/logos/logo_g-srs.png alt Logo
G-SRS /a ;